morpholinoanthracycline mx2 has been researched along with nogalamycin in 1 studies
| Studies (morpholinoanthracycline mx2) | Trials (morpholinoanthracycline mx2) | Recent Studies (post-2010) (morpholinoanthracycline mx2) | Studies (nogalamycin) | Trials (nogalamycin) | Recent Studies (post-2010) (nogalamycin) |
|---|---|---|---|---|---|
| 53 | 15 | 0 | 231 | 20 | 18 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bungo, M; Fujiwara, Y; Fukuda, M; Horichi, N; Minato, K; Nakagawa, K; Niimi, S; Ohe, Y; Saijo, N; Sasaki, Y | 1 |
1 other study(ies) available for morpholinoanthracycline mx2 and nogalamycin
| Article | Year |
|---|---|
In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Carubicin; Cisplatin; Daunorubicin; Doxorubicin; Drug Resistance; Humans; Menogaril; Mitomycins; Nogalamycin; Tumor Cells, Cultured | 1989 |